IXICO Plc IXI

4:15pm: Stocks rebound Wall Street finished mostly higher Thursday as stocks recovered from an early pullback, helped by a retreat in Treasury yields and gains in semiconductor shares. The Dow Jones Industrial Average edged up 21 points, or less than 0.1%, to 50,926, while the S&P 500...

Rising UK borrowing costs, highlighted by the recent jump in 10 year gilt yields ahead of the next budget, are forcing investors to think harder about where future growth could come from. That is one reason artificial intelligence in healthcare is getting more attention. This piece looks at three UK focused AI healthcare stocks from our screener that aim to tap into this shift and explains what each one offers. The three stocks covered below are just a sample, and the full screen surfaced 5...

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains unchanged after two clients discontinued Huntington's disease programmes it was supporting. The AIM-listed company said the cancellations would reduce...

Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging company, rose 11% to 9p after it has raised its revenue forecast for the current financial year after stronger-than-expected trading. The company now expects revenues of at least £8 million for the year ending 30...

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) chief scientific and medical officer Robin Wolz tells Proactive's Stephen Gunnion that three internationally recognised specialists have joined the company's Scientific Advisory Board — two in Alzheimer's disease and one in Parkinson's — as the company deepens its position in neurodegenerative disease research. A new collaboration with the Paris Brain Institute will focus on next-generation MRI biomarkers for Parkinson's, while two IXICO scientists have been invited to contribute to the Michael J. Fox Foundation's MRI Advisory Committee. Wolz is direct

Quantum Blockchain Technologies PLC (AIM:QBT, FRA:BYA1) says it has cleared a key data hurdle in developing its Method C AI Oracle, with the first version now potentially ready as early as the end of June. CEO Francesco Gardin admits the process "took longer than expected" but says the company is now in a position to train its learning models and move into live testing. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has added three senior Alzheimer's and Parkinson's specialists to its advisory board and launched a new research collaboration with the Paris Brain Institute. The work focuses on neurome

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO, Bram Goorden, talked with Proactive about the company’s interim results, highlighting strong revenue growth, expanding demand in Alzheimer’s disease clinical trials and the company’s evolving TechBio strategy. Goorden said IXICO delivered “23%...

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and analytics group, has secured £1.3 million of new contract work that its broker says should take the company's order book close to full coverage of its current-year revenue forecast. The two wins, an Alzheimer's disease...

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has won £1.3 million of new contracts, including work to validate a blood-based Alzheimer's biomarker test for FDA clearance and an extended Huntington's disease trial. CEO Bram Goorden says the wins hit three key components of the company's growth strategy. Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has reported its first commercial revenue from its Stereax solid-state battery range after delivering an initial batch to US partner Cirtec Medical. The company is also expanding its larger Goliath battery into defence and consumer markets, including a joint

Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) delivered a strong first quarter, with revenue up to $74.3 million and net income rising to $46.7 million as a gold price of $4,820 per ounce more than offset lower sales volumes. The company is on track for 75,000 to 85,000 ounces of production this year and is advancing toward a final investment decision at its Douta project in Senegal. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) is guiding for at least 15% revenue growth this year after a strong first half, with revenue up 23% and its order book growing 38% to £18.1 million. A £10

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Stephen Gunnion to discuss the company’s interim results, growing Alzheimer’s trial demand and expanding TechBio strategy. Goorden said IXICO delivered 23% revenue growth and a 38% increase in its order book, with strong visibility into FY2026 revenues. Growth has been driven by new contracts, study extensions and increasing momentum in later-stage Alzheimer’s programmes. He also highlighted expanding opportunities in neurodegenerative diseases, including Parkinson’s, and growing partnerships in diagnostics and blood-based bioma

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) has picked up a $3.8 million order for its Guardian driver monitoring system from a leading North American autonomous driving company. CEO Paul McGlone says fourth-quarter Guardian revenue has already exceeded the entire third quarter, pointing to real momentum in the aftermarket division. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has launched version 10 of its IXI neuroimaging platform, bringing faster processing, greater data capacity and improved image analysis for clinical trials. The upgrade also supports the company's broader TechBio strat

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has released the tenth version of its proprietary IXI platform, bringing improvements to processing speed, data capacity and image analysis precision. The London-based group uses artificial...

Bango PLC (AIM:BGO, OTCQX:BGOPF) has won direct carrier billing mandates in Hong Kong and Latvia, taking business from incumbent providers. Bango now supports four of Hong Kong's five mobile operators offering direct carrier billing for Google Play. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) is expecting first-half revenues to rise 23% to £3.9 million, with its order book up 38% to £18.1 million. The neuroscience data company completed a £10 million fundraise in March to support its growth strategy. ACG Metals Ltd (LSE:ACG, OTC:ACGAF) reported a lower first quarter as expected, with gold equival